10-K: Processa Pharmaceuticals Files 10-K, Prioritizes Oncology Pipeline

Processa Pharmaceuticals' 10-K filing highlights a strategic shift towards Next Generation Chemotherapy (NGC) oncology drugs, while reporting a net loss of $11.1 million for 2023.

Summary

• Processa Pharmaceuticals is now prioritizing its Next Generation Chemotherapy (NGC) oncology drug pipeline, which includes NGC-Capecitabine, NGC-Gemcitabine, and NGC-Irinotecan.
• The company reported a net loss of $11.1 million for the year ended December 31, 2023, compared to a net loss of $27.4 million in 2022.
• Research and development expenses decreased to $5.8 million in 2023 from $11.5 million in 2022, primarily due to the completion of a Phase 2A trial and the termination of another.
• General and administrative expenses also decreased to $5.7 million in 2023 from $8.8 million in 2022, mainly due to a reduction in stock-based compensation.
• The company completed a Phase 2A trial for PCS12852 in gastroparesis patients with positive results and terminated a Phase 2 trial for PCS499 due to enrollment difficulties.
• Processa had $4.7 million in cash and cash equivalents at the end of 2023 and raised an additional $6.3 million in net proceeds in January 2024.
• The company plans to use the recent funding to advance the Phase 2 trial for NGC-Cap in breast cancer, with patient enrollment expected to begin in the third quarter of 2024.
• The company is exploring options to monetize non-core drug assets, including out-licensing or partnering opportunities.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there's a strategic shift towards a promising pipeline and reduced losses, the company's financial position remains precarious, with a going concern warning and the need for future capital raises. The positive clinical trial results are encouraging, but the overall sentiment is neutral due to the financial risks.

Positives

• The company's net loss significantly decreased in 2023 compared to 2022.
• Research and development expenses were reduced, indicating improved cost management.
• The company successfully completed a Phase 2A trial for PCS12852 with positive results.
• The company secured additional funding of $6.3 million in January 2024.
• The company has a clear strategic focus on its NGC oncology drug pipeline.
• The FDA has agreed that data from past and existing studies could be used to directly support the Phase 2 trial in breast cancer for NGC-Cap.

Negatives

• The company reported a net loss of $11.1 million for 2023.
• The company terminated a Phase 2 trial for PCS499 due to enrollment difficulties.
• The company has a history of losses and may never become profitable.
• The company has limited cash resources and will require additional financing.
• The company's financial statements contain a statement regarding a substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to obtain funding for future clinical trials and operations is uncertain.
• The company's licenses are subject to termination by the licensor in certain circumstances.
• The company depends entirely on the successful development of its product candidates, which have not yet demonstrated efficacy in clinical trials.
• The company is completely dependent on third parties to manufacture its product candidates.
• The company could face competition from other biotechnology and pharmaceutical companies.
• The company relies on third parties to conduct clinical trials for its product candidates.
• The company's product candidates may infringe the intellectual property rights of others.
• The company's failure to maintain compliance with Nasdaq's continued listing requirements could result in the delisting of its common stock.
• The company's common stock price is expected to be volatile.

Future Outlook

The company plans to use the recent funding to advance the Phase 2 trial for NGC-Cap in breast cancer, with patient enrollment expected to begin in the third quarter of 2024. The company also plans to meet with the FDA to discuss potential study designs for NGC-Gem in 2024 and conduct IND-enabling and toxicology studies for NGC-Iri in 2024-2025. The company expects to incur additional losses in the future and will need to raise additional capital to fully implement its business plan.

Management Comments

• Our mission is to provide better treatment options than those that presently exist by extending a patients survival and/or improving a patients quality of life.
• We believe utilizing our regulatory science approach provides us with three distinct advantages: greater efficiencies, greater possibility of drug approval, and greater ability to evaluate the benefit-risk of a drug.
• Our strategic prioritization is to advance our pipeline of NGC proprietary small molecule oncology drugs.
• We believe our NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts.
• We continue to be focused on drug products that improve the survival and/or quality of life for patients by improving the safety and/or efficacy of the drug in a targeted patient population, while providing a more efficient and probable path to FDA approval and differentiating our drugs from those on the market or are currently being developed.

Industry Context

The shift towards NGC drugs aligns with the industry's focus on improving existing treatments by modifying their metabolism and distribution, potentially leading to better safety and efficacy profiles. The company's focus on regulatory science and the FDA's Project Optimus initiative also reflects a broader trend towards more science-based drug development.

Comparison to Industry Standards

• Processa's approach of modifying existing FDA-approved cancer drugs is a departure from the traditional focus on novel drug discovery, which is common among many biotech companies.
• The company's focus on improving the safety and efficacy profiles of existing drugs is similar to the strategies of companies like BioXcel Therapeutics, which focuses on developing novel formulations of existing drugs.
• Processa's emphasis on regulatory science and the FDA's Project Optimus initiative is comparable to companies like Agios Pharmaceuticals, which prioritizes understanding the dose-response relationship of their drugs.
• Unlike companies like Moderna and BioNTech, which focus on novel technologies like mRNA, Processa is focused on small molecule drugs with well-established mechanisms of action.
• Processa's decision to prioritize breast cancer for NGC-Cap is similar to the strategies of companies like Puma Biotechnology, which focuses on developing therapies for specific cancer types.

Corporate Governance

Related Party Transactions

• CorLyst, LLC, a related party, reimbursed the company for shared costs related to payroll, health insurance, and rent, totaling $112,000 in 2023 and $124,000 in 2022.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment due to the company's financial challenges.
• Employees may experience uncertainty due to the company's financial instability and potential changes in operations.
• Customers (potential patients) may benefit from the development of new and improved cancer treatments.
• Suppliers and creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company plans to begin enrolling patients in the Phase 2 trial for NGC-Cap in breast cancer in the third quarter of 2024.
• The company plans to meet with the FDA to discuss potential study designs for NGC-Gem in 2024.
• The company plans to conduct IND-enabling and toxicology studies for NGC-Iri in 2024-2025.
• The company will continue to evaluate options to monetize non-core drug assets.

Key Dates

Keywords

Next Generation Chemotherapy, NGC, oncology, clinical trials, biopharmaceutical, drug development, PCS6422, PCS3117, PCS11T, cancer, FDA, regulatory science, Project Optimus, breast cancer, gastroparesis